Objective-Patients with diabetes mellitus have an increased risk of suffering atherothrombotic syndromes and are prone to clustering cardiovascular risk factors. However, despite their dysregulated glucose metabolism, intensive glycemic control has proven insufficient to reduce thrombotic complications. Therefore, we aimed to elucidate the determinants of thrombosis in a model of type 2 diabetes mellitus with cardiovascular risk factors clustering. Methods and Results-Intravital microscopy was used to analyze thrombosis in vivo in Zucker diabetic fatty rats (ZD) and lean normoglycemic controls. Bone marrow (BM) transplants were performed to test the contribution of each compartment (blood or vessel wall) to thrombogenicity. ZD showed significantly increased thrombosis compared with lean normoglycemic controls. BM transplants demonstrated the key contribution of the hematopoietic compartment to increased thrombogenicity. Indeed, lean normoglycemic controls transplanted with ZD-BM showed increased thrombosis with normal glucose levels, whereas ZD transplanted with lean normoglycemic controls-BM showed reduced thrombosis despite presenting hyperglycemia. Significant alterations in megakaryopoiesis and platelet-endoplasmic reticulum stress proteins, protein disulfide isomerase and 78-kDa glucose-regulated protein, were detected in ZD, and increased tissue factor procoagulant activity was detected in plasma and whole blood of ZD. 
T he link between diabetes mellitus and cardiovascular disease is well established, as patients with diabetes mellitus have an increased risk of developing ischemic syndromes [1] [2] [3] [4] [5] [6] [7] and are particularly prone to clustering various cardiovascular risk factors, such as obesity, [8] [9] [10] [11] hypercholesterolemia, and hypertension, and with a stronger negative impact than that observed in patients without diabetes mellitus. 7 Although hyperglycemia has been associated with cardiovascular disease and acute event occurrence, [12] [13] [14] recent clinical trials (ie, Action to Control Cardiovascular Risk in Diabetes 2, [15] [16] [17] [18] have shown that intensive glycemic control is insufficient to reduce cardiovascular event presentation.
Numerous alterations have been previously described in hemostasis 8, [19] [20] [21] [22] [23] and platelet activity [19] [20] [21] [24] [25] [26] [27] and in the vascular endothelial function [19] [20] [21] [28] [29] [30] among patients with diabetes mellitus, altogether contributing to the development of a characteristic proatherothrombotic state. However, the degree of contribution of each compartment (blood or vessel wall) to the increased thrombotic risk has not been elucidated. Thus, in the present study we aimed to (1) evaluate, in a rat model of type 2 diabetes mellitus with cardiovascular risk factor clustering, whether the presence of hyperglycemia plays a role in the increased thrombotic risk; and (2) evaluate the contribution of platelets and the vessel wall to the increased prothrombotic risk.
Our results indicate that megakaryopoiesis is altered in the bone marrow (BM) of diabetic animals, giving rise to hyperreactive platelets with altered expression of endoplasmic reticulum (ER) stress proteins, 78-kDa glucose-regulated protein (GRP78) and protein disulfide isomerase (PDI), which can increase the amount of active tissue factor (TF), thus contributing to increased thrombotic risk in diabetic animals independently of blood glucose levels.
Materials and Methods

Animals
The study was developed in 3 phases: (1) 8-week-old Zucker diabetic fatty rats (ZD) and their corresponding lean normoglycemic controls (ZC) were fed with Lab Diet 5008 (PMI Nutrition International, St. Louis, MO) chow for 5 weeks, and thrombotic risk was evaluated in vivo by photochemically induced thrombosis monitored by intravital microscopy; (2) BM from ZC donors was transplanted to age-matched ZC (ZC-BM/ZC) and ZD (ZC-BM/ZD) recipients, and animals were tested for thrombotic risk; and (3) BM from ZD donors that had already developed type 2 diabetes mellitus was transplanted to age-matched ZC hosts (ZD-BM/ZC). As a proof of concept, Wistar rats received BM from age-matched green fluorescent proteintransgenic Wistar rats.
All procedures fulfilled the criteria established by the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the Internal Animal Committee Review Board.
In Vivo Real-Time Thrombosis Evaluated by Intravital Microscopy
Rose Bengal was administered to anesthetized animals through the femoral vein, and a portion of the mesentery was extended flat on the microscope stage. Within 30 minutes of Rose Bengal administration, mesenteric vessels were irradiated to produce photochemical endothelial injury until a full thrombotic occlusion was achieved. Irradiation times necessary to produce a full occlusion (occlusion time [OT]) were determined.
Bone Marrow Transplants
Recepients received combined immunosuppressive therapy (cyclophosphamide and busulfan) before transplantation. Femurs and tibias were isolated from the donors and BM was flushed with Dulbecco Modified Eagle Media. 3×10
7 BM nucleated cells were injected to immunosuppressed recipients through the lateral tail vein. Blood cell counts were performed to assess the effect of the immunosuppressive treatment, as well as posttransplantation recovery.
Reticulated Platelet Quantification
Reticulated platelets were analyzed by flow cytometry after staining citrate-anticoagulated blood with thiazole orange.
Platelet Turnover
Platelets were biotinylated and blood samples were extracted 3 hours after administration and daily for the 6 following days. Citrateanticoagulated samples were incubated with streptavidin and analyzed by flow cytometry.
Tissue Factor Procoagulant Activity Determination and Thromboelastometry
TF procoagulant activity was measured in plasma from citrateanticoagulated blood using a factor Xa generation test, as previously described. 31, 32 Citrate-anticoagulated whole blood was used to analyze dynamic blood clot formation with the ROTEM coagulation analyzer (Pentapharm GmbH Diagnostic Division, Munich, Germany).
Megakaryocyte Ploidy
BM cells were isolated from femurs and tibias, stained with an antibody against CD61, incubated with propidium iodide, and then analyzed for propidium iodide content by flow cytometry.
Statistical Analysis
Results were expressed as mean±SEM. Student t test or 1-way ANOVA, as appropriate, were used to determine statistical significance between the groups. A P<0.05 was considered significant. An extended Methods section is available in the online-only Data Supplement.
Results
Group Characteristics
ZD were diabetic with cardiovascular risk factor clustering. Indeed, ZD were obese and showed atherosclerotic dyslipidemia with significantly increased non-high density lipoprotein cholesterol levels and hypertriglyceridemia (Table 1) . Insulin levels of ZD were also significantly increased compared with those of ZC (Table 1) , reflecting the existence of insulin resistance. Fasting blood glucose levels of ZD were nearly 5-fold higher than those of ZC.
Thrombosis and Coagulation
In vivo photochemically induced thrombus formation ( Figure 1A ) was monitored by real-time intravital microscopy, and time needed to produce vessel occlusion was determined. Short OTs reflected the existence of a prothrombotic tendency, whereas prolonged OTs showed a reduced thrombotic risk in the presence of vascular damage.
ZD had a higher thrombotic risk than that of ZC, as their OTs were significantly shorter ( Figure 1B; 
Hematopoietic Versus Vessel Wall Contribution to Thrombogenicity
BM transplantation experiments between ZC and ZD animals allowed us to determine the relative contribution of each compartment to thrombogenicity. The behavior of platelets shed by ZD-BM in a normoglycemic environment was analyzed in contrast to that of ZC-BM-derived platelets in a milieu of hyperglycemia with other cardiovascular risk factors. Indeed, BM transplantation showed no effect over the metabolic profile of the recipients (Table 2) as, in line with nontransplanted groups, ZD recipients transplanted with ZC-BM (ZC-BM/ZD) were obese and showed significantly increased fasting blood glucose, triglycerides, total, non-high density lipoprotein, and low-density lipoprotein cholesterol levels compared with ZC recipients transplanted with both ZC-BM (ZC-BM/ZC) and ZD-BM (ZD-BM/ZC). In line with these results, BM transplantation per se did not alter thrombogenicity, as no significant differences were observed between OTs of ZC-BM/ZC animals ( Figure 1C Interestingly, when ZD-BM was transplanted to ZC recipients (ZD-BM/ZC), animals became ZD-like, as their OTs were significantly reduced compared with those of nontransplanted ZC ( Figure 1C ; ZD-BM/ZC, 0.93±0.17 minutes; P<0.005 vs ZC and ZC-BM/ZC) and became similar to those of nontransplanted ZD rats ( Figure 1B ; ZD, 1.00±0.05 min) despite showing normal blood glucose levels (Table 2) . Conversely, transplantation with ZC-BM transformed ZD recipients (ZC-BM/ZD) into ZC-like by significantly increasing their OTs compared with those of nontransplanted ZD ( Figure 1C ; 5.94±0.61 minutes; P<0.0001) despite their increased glucose levels (Table 2) . Thus, these results highlight the greater contribution of platelets produced by the BM to the increased thrombogenicity observed in ZD animals compared with that of the vessel wall and show a lack of effect of blood glucose levels over the thrombotic response.
Donor BM engraftment in the recipients was confirmed by the presence of green fluorescent protein-positive cells in the femur of wild-type recipients 5 weeks after receiving BM from green fluorescent protein-transgenic Wistar rat donors ( Figure I in the online-only Data Supplement). Routine controls to assure the effectiveness of the immunosuppressive protocol before transplantation, as well as to confirm posttransplantion recovery of all hematological parameters (red blood cells, hematocrit, platelet, and white blood cell) were performed in all transplanted animals (Table I in the online-only Data Supplement). Such analyses revealed that the immunosuppressive treatment led to a significant reduction in white blood cell counts in all transplanted groups at day 0 (transplant) compared with the corresponding nontransplanted groups and a gradual recovery of all the hematological parameters. In fact, ZC-BM/ ZD and ZD-BM/ZC showed no significant differences at day 28 with the corresponding nontransplanted groups. . t=−15 seconds: vessel before irradiation. t=5 seconds: 5 s after irradiation starts thrombus formation begins. As irradiation continues (t=15 seconds and t=50 seconds), the thrombus grows until achieving a full occlusion. B, ZD showed significantly shorter OTs than lean normoglycemic controls (ZC). C, Bone marrow (BM) transplantation had no effect on OTs (no significant differences between ZC and ZC-BM/ZC). However, ZD-BM significantly reduced OTs of ZC recipients to those of nontransplanted ZD and ZC-BM significantly increased OTs in ZD recipients. *P<0.001 vs ZC. 
Platelet Size and Activation
The fact that thrombotic risk was transferred by BM transplantation allowed us to conclude that the main modification affecting thrombogenicity in ZD animals was in the hematopoietic compartment. Therefore, we analyzed numerous factors that could contribute to such increased thrombotic risk. First, mean platelet volume analysis showed that ZD platelets were significantly larger (Figure 2A ; 6.78±0.09 μm 3 ) than those of ZC (Figure 2A ; 6.24±0.03 μm 3 ; P<0.0001), and the flow cytometric analysis of CD62P expression ( Figure 2B ) indicated that platelet susceptibility to activation was significantly increased in ZD animals compared with ZC. Moreover, despite the fact that platelets from both groups responded in a dose-dependent manner to thrombin, the percentage of CD62P+ platelets in ZD animals was significantly higher than that of ZC at all doses tested ( Figure 2B ).
Reticulated Platelets and Platelet Turnover
ZD showed significantly more reticulated platelets ( Figure 2C ) than ZC, indicating an increase in the platelet production by the BM of such animals. Thus, we performed a platelet turnover analysis in both groups. In agreement with what we observed in reticulated platelets, ZD showed an increased platelet turnover ( Figure 2D ), as the percentage of streptavidin-positive platelets observed in that group was significantly lower than that of ZC at 24, 48, and 72 hours after administration of biotin-N-Hydroxysuccinimide. The observed increased platelet turnover was a result of a combination of accelerated death, reflected by a marked reduction of the absolute number of biotinylated platelets in ZD during the first 72 hours postbiotinylation ( Figure 2E ) compared with ZC, and an increased platelet production shown by an increased amount of nonbiotinylated platelets in such animals ( Figure 2F ). Interestingly, no differences were observed in the number of megakaryocytes present in the BM of both groups ( Figure 3B ) nor in their ploidy ( Figure 3C-3E ).
Platelet TF and ER Stress Proteins Expression
TF protein expression was analyzed in platelets from ZD and ZC ( Figure 4A ) and ER stress proteins previously associated with active TF regulation, GRP78 and PDI, were then investigated.
No differences were observed in the platelet TF expression between ZD and ZC. However, GRP78 (found to exert an antithrombotic effect by inhibiting active TF by direct binding) [33] [34] [35] expression was found to be significantly reduced in platelets from ZD animals compared with those of ZC ( Figure  4B ; 1.65±0.37 AU and 2.81±0.37 AU, respectively; P<0.05), whereas PDI (a thiol isomerase and oxidoreductase that contributes to TF decryption and increases TF procoagulant activity) expression was significantly increased in ZD compared with ZC ( Figure 4C ; 0.47±0.04 AU and 1.05±0.06 AU; P<0.0001).
Plasma TF Procoagulant Activity and Coagulation Pathway Analysis
TF procoagulant activity in plasma of ZD animals was significantly increased compared with ZC ( Figure 4D ; 0.15±0.01 U/mL and 0.08±0.00 U/mL, respectively; P=0.0004).
Thromboelastometry confirmed an increase in the activity of the extrinsic (TF-dependent) coagulation pathway ( Figure 4E ) in ZD rats, reflected by a significantly reduced extrinsically activated assay clotting time (extrinsically activated assay Ct=42.0±1.7 seconds) compared with ZC (54.0±0.0 seconds; P<0.05). However, no significant differences were observed in the activity of the intrinsic coagulation pathway between ZD and ZC (intrinsically activated assay Ct=80.4±4.7 seconds and 86.0±12.0 seconds, respectively; P>0.05). No significant differences were observed between groups in clot properties (clot formation time or maximum clot firmness; data not shown) in either the extrinsically activated or intrinsically activated assays.
Discussion
In this study, we have shown that the increased thrombotic risk observed in diabetes mellitus with clustering of cardiovascular risk factors is independent of blood glucose levels and associated with a modification in platelets produced by diabetic BM megakaryocytes. Indeed, we demonstrate for the Figure 2 . Platelet size, activation in response to thrombin, and turnover. A, Mean platelet volume was significantly increased in Zucker diabetic fatty rats (ZD) compared with lean normoglycemic controls (ZC). B, Platelets from ZD and ZC showed a dosedependent increase in CD62P+ platelets. However, activation was significantly higher in ZD platelets at all tested doses. C, ZD showed significantly more reticulated platelets than ZC. D, ZD showed an increased platelet turnover compared with ZC with significantly less streptavidin-positive platelets at 24, 48, and 72 hours after biotin-N-Hydroxysuccinimide administration than ZC. E, ZD showed an accelerated platelet death in the first 72 hours after biotinylation. F, ZD showed increased platelet production, showing higher nonbiotinylated platelet counts than ZC at nearly all time points. *P<0.05 vs ZC.
first time by a transplant crossover study that hematopoieticderived blood alterations, rather than those of the vessel wall, greatly contribute to the detected increased thrombotic risk and that alterations in platelet expression of ER stress proteins, PDI and GRP78, likely contribute to the overall detected prothrombotic phenotype.
Various clinical trials have shown that intensive glycemic control, despite achieving near-normal blood glucose levels (≈6.0%-6.5% HbA1c), does not reduce acute ischemic events. 2, [15] [16] [17] [18] In fact, our results show that, despite the nearly 3.5-fold difference in blood glucose levels, ZC animals transplanted with ZD-BM present the same thrombotic risk as nontransplanted ZD animals (reflected by short OTs upon injury), confirming that hyperglycemia has no direct effect over thrombogenicity. Crossed BM transplantation experiments have allowed us to discriminate the contribution of the hematopoietic compartment and the vessel wall to the prothrombotic behavior observed in the ZD animals. Transplantation per se showed no effect over the thrombotic behavior as no significant differences were observed between ZC transplanted with ZC-BM and those of nontransplanted ZC. However, ZC recipients transplanted with ZD-BM were transformed in ZD-like animals with short OTs despite their normal blood glucose levels, whereas ZD recipients of ZC-BM dramatically increased their OTs behaving as ZC-like animals despite showing hyperglycemia. Therefore, our results highlight the contribution of the hematopoietic compartment to the increased thrombotic risk observed in diabetes mellitus. Interestingly, platelets produced by ZC-BM were insensitive to the hyperglycemic environment of ZD, raising the question of whether ZC animals might be resistant to hyperglycemia because of their genetic background. Further analyses are required to clarify this point.
ZD animals showed an increased platelet turnover compared with ZC, possibly because of the combination of accelerated death with increased production of new platelets. According to this observation, ZD showed an increased number of reticulated platelets, the youngest and more immature platelets. However, no differences were observed in megakaryocyte number or ploidy between ZD and ZC in contrast to previous observations where diabetic subjects showed an increased mean ploidy compared with controls. 38 Yet, the biological significance of megakaryocyte ploidy remains unclear, and it has previously been described that ploidy and platelet size are independent. 39 Thus, our results suggest that alterations observed in ZD probably occur during platelet formation or maturation. The observed alterations in platelet turnover might contribute to explain the fact that ZD showed increased platelet number and size compared with ZC as immature platelets are larger in size. Interleukin-6 likely contributes to enhance megakaryopoiesis in ZD, as increased interleukin-6 levels have been previously observed in these animals [40] [41] [42] (in line with that observed in obese and patients with diabetes mellitus), and interleukin-6 has been proven to increase platelet count by inducing hepatic synthesis of thrombopoietin, the main regulator of megakaryopoiesis. 8, 43, 44 Moreover, ZD platelets also showed an increased activation in response to thrombin, which together with their increased size reflects a hyperreactive state, as large platelets are more reactive and aggregable because of the fact that they contain denser granules, secrete more serotonin and β-thromboglobulin, and produce more thromboxane A2. 27, [45] [46] [47] [48] In fact, mean platelet volume is clinically considered as an index of platelet activity, as increased platelet size has been linked to increased cardiovascular risk in both diabetic and nondiabetic subjects. 24, 25, [45] [46] [47] [48] Diabetes mellitus, 49-51 hypercholesterolemia, 52, 53 and obesity 54, 55 (all present in ZD animals) have all been described to induce ER stress in various cell types. When such stress is sensed, cells activate the unfolded protein response (UPR) to restore normal ER function. [56] [57] [58] GRP78 is the main control of the UPR acting as a negative regulator of the inositol requiring kinase 1, the activating transcription factor 6, and the protein kinase-like ER kinase signaling cascades. 57, 59 Therefore, our observation that GRP78 protein expression is reduced in platelets from ZD animals, which is in line with previous data in liver cells, 60 ,61 might be part of the response against prolonged ER stress. However, it has also previously been shown that PDI exerts a more effective role in alleviating ER stress than GRP78. 62 Thus, the increase observed in PDI expression in ZD might also be caused by the need to reduce ER stress.
Interestingly, our data show that diabetes mellitus with cardiovascular risk factor clustering induces alterations in ER stress proteins in the BM and that platelets produced by such marrow have expression levels of GRP78 and PDI that confer an increased thrombogenicity to ZD animals. Indeed, both GRP78 and PDI have been associated with the regulation of TF activation.
The origin of platelet TF is currently under debate. Traditionally, it was assumed that platelets did not synthesize TF and only bound blood-borne TF-bearing microparticles (mostly originating from leucocytes) in their membrane when they became activated. However, various studies have now reported the presence of TF in platelets [63] [64] [65] and TF-mRNA has also been detected in unstimulated platelets. 66 Nevertheless, the mere presence of TF does not imply a prothrombotic behavior as TF procoagulant activity is tightly regulated. Indeed, it has previously been described that only a fraction of TF is functionally active in coagulation, 67, 68 whereas the vast majority of it remains encrypted. In fact, we have detected no differences in TF protein content between ZD and ZC but significantly different procoagulant activity.
GRP78 is a multifunctional protein usually found in the lumen of the ER that has also been described to be present in the cell surface. In fact, cell-surface GRP78 has been proven to exert an atheroprotective function in platelets 34 and endothelial cells 33, 35 inhibiting TF's procoagulant activity by direct binding. On the other hand, PDI is a ubiquitously expressed thiol isomerase and oxidoreductase that has been described to contribute to TF's decryption and to increase TF procoagulant activity even though the mechanism still remains unclear. [68] [69] [70] [71] [72] [73] Thus, the decreased levels of GRP78 observed in platelets from ZD animals together with the increased levels of PDI seem to contribute to the increased TF procoagulant activity observed in such animals.
In summary, our data indicate that thrombotic risk in diabetic animals with cardiovascular risk factor clustering remains high Tissue factor (TF) activity and platelet TF, protein disulfide isomerase (PDI), and 78-kDa glucose-regulated protein (GRP78) expression. A, Platelet TF, PDI, and GRP78 expression. B, GRP78 was significantly reduced in Zucker diabetic fatty rats (ZD) platelets and PDI (C) was significantly increased. D, Plasma TF procoagulant activity was significantly increased in ZD. E, ZD showed increased TF-dependent coagulation. *P<0.05 vs lean normoglycemic controls (ZC). PLT indicates platelet; EXTEM Ct, extrinsically activated assay clotting time.
even when blood glucose levels are reduced to normal levels and, hence, seems independent of glycemia. Although many regulatory factors may be involved in the increased thrombotic response of diabetic subjects (including the mechanisms controlling thrombopoiesis), our data show that platelet thrombotic tendency is enhanced by disturbances in ER stress proteins induced in their parent cells in the BM. Particularly, decreased GRP78 and increased PDI expression may contribute to the higher thrombotic risk observed in diabetes mellitus because both PDI and GRP78 have been shown to regulate TF activity and, hence, thrombogenicity. However, further studies in human diabetic platelets are needed to translate these experimental studies into the clinical scenario.
